Izonsteride

Drug Profile

Izonsteride

Alternative Names: LY 320236

Latest Information Update: 09 Oct 2007

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; University of Chicago Cancer Research Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 27 Oct 2000 A clinical study in patients with prostate cancer has been added to the adverse events section and Cancer therapeutic trials section
  • 03 Mar 1999 Two studies have been added to the pharmacodynamics section ,
  • 14 Jun 1996 Phase-I clinical trials for Prostate cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top